NZ330596A
(en)
*
|
1998-06-05 |
2001-02-23 |
Dec Res |
Intravaginal devices allowing for increased uptake of active ingredients
|
US7588793B1
(en)
|
1998-06-05 |
2009-09-15 |
Cadbury Adams Usa, Llc |
Enhanced flavoring compositions containing N-ethyl-p-menthane-3-carboxamide and method of making and using same
|
HUP0104778A3
(en)
|
1998-12-24 |
2004-05-28 |
Janssen Pharmaceutica Nv |
Controlled release galantamine composition
|
ATE400251T1
(de)
*
|
1999-02-09 |
2008-07-15 |
Pfizer Prod Inc |
Zusammensetzungen basischer arzneistoffe mit verbesserter bioverfügbarkeit
|
AU3900300A
(en)
|
1999-03-24 |
2000-10-09 |
Fmc Corporation |
Improved aqueous solubility pharmaceutical formulations
|
GB9913932D0
(en)
|
1999-06-15 |
1999-08-18 |
Pfizer Ltd |
Purine derivatives
|
WO2001002393A1
(en)
*
|
1999-07-01 |
2001-01-11 |
Italfarmaco S.P.A. |
Complexes of paroxetine, with cyclodextrins or cyclodextrin derivatives
|
WO2001001955A1
(en)
*
|
1999-07-02 |
2001-01-11 |
Janssen Pharmaceutica N.V. |
Nasal formulation of an antifungal
|
CA2315614C
(en)
|
1999-07-29 |
2004-11-02 |
Pfizer Inc. |
Pyrazoles
|
GB9923045D0
(en)
*
|
1999-09-29 |
1999-12-01 |
Novartis Ag |
New oral formulations
|
GB9924361D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Ltd |
Purine derivatives
|
GB9924363D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Central Res |
Purine derivatives
|
CA2726789A1
(en)
|
2000-02-05 |
2001-11-08 |
Theravance, Inc. |
Cyclodextrin containing glycopeptide antibiotic compositions
|
US6835717B2
(en)
|
2000-03-08 |
2004-12-28 |
The Johns Hopkins University School Of Medicine |
β-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases
|
SG98393A1
(en)
|
2000-05-19 |
2003-09-19 |
Inst Materials Research & Eng |
Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
|
DK1284974T3
(da)
|
2000-05-26 |
2004-06-07 |
Pfizer |
Triazolyltropanderivater som CCR5-modulatorer
|
US6667314B2
(en)
|
2000-05-26 |
2003-12-23 |
Pfizer, Inc. |
Tropane derivatives useful in therapy
|
CN1322850C
(zh)
*
|
2000-06-02 |
2007-06-27 |
沈阳药科大学 |
盐酸尼卡地平粉针剂及其制备方法
|
US6753322B2
(en)
|
2000-06-06 |
2004-06-22 |
Pfizer Inc |
2-aminocarbonyl-9H-purine derivatives
|
GB0015239D0
(en)
*
|
2000-06-21 |
2000-08-16 |
Biochemie Gmbh |
Organic compounds
|
US6921753B2
(en)
|
2000-06-27 |
2005-07-26 |
Pfizer Inc |
Purine derivatives
|
US6420557B1
(en)
|
2000-07-28 |
2002-07-16 |
Pfizer Inc. |
Crystalline therapeutic agent
|
PE20020300A1
(es)
|
2000-08-22 |
2002-05-10 |
Pharmacia Corp |
Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
|
GB0022695D0
(en)
|
2000-09-15 |
2000-11-01 |
Pfizer Ltd |
Purine Derivatives
|
AR031135A1
(es)
|
2000-10-10 |
2003-09-10 |
Upjohn Co |
Composiciones de antibiotico topico para el tratamiento de infecciones oculares
|
US6548508B2
(en)
|
2000-10-20 |
2003-04-15 |
Pfizer, Inc. |
Use of PDE V inhibitors for improved fecundity in mammals
|
JP2004517127A
(ja)
|
2000-12-21 |
2004-06-10 |
ネクター セラピューティックス |
ポリエン抗真菌剤の肺送達
|
US6579898B2
(en)
|
2001-03-01 |
2003-06-17 |
Pfizer Inc. |
Compositions having improved bioavailability
|
CA2443449C
(en)
|
2001-04-10 |
2008-11-04 |
Pfizer Inc. |
Pyrazole derivatives for treating hiv
|
GB0116453D0
(en)
|
2001-07-05 |
2001-08-29 |
Imp College Innovations Ltd |
Method
|
FR2827516B1
(fr)
*
|
2001-07-19 |
2003-09-19 |
Servier Lab |
Composition pharmaceutique pour l'administration par voie nasale d'estradiol et de norethisterone
|
US6653339B2
(en)
|
2001-08-15 |
2003-11-25 |
Pfizer Inc. |
Method of treating irritable bowel syndrome
|
CN100384865C
(zh)
*
|
2001-11-02 |
2008-04-30 |
嵌入治疗公司 |
用于rna干扰的治疗用途的方法及组合物
|
CA2363376A1
(en)
*
|
2001-11-16 |
2003-05-16 |
Bernard Charles Sherman |
Solid pharmaceutical compositions for oral administration comprising itraconazole
|
GB0129273D0
(en)
|
2001-12-06 |
2002-01-23 |
Pfizer Ltd |
Crystalline drug form
|
MXPA04007737A
(es)
|
2002-02-11 |
2004-10-15 |
Pfizer |
Derivados de nicotinamida utiles como inhibidores de fosfodesterasas 4.
|
US6756392B2
(en)
|
2002-02-11 |
2004-06-29 |
Pfizer Inc |
Nicotinamide derivatives useful as PDE4 inhibitors
|
US8128957B1
(en)
|
2002-02-21 |
2012-03-06 |
Valeant International (Barbados) Srl |
Modified release compositions of at least one form of tramadol
|
GB0207104D0
(en)
|
2002-03-26 |
2002-05-08 |
Pfizer Ltd |
Stable hydrate of a muscarinic receptor antagonist
|
US6855724B2
(en)
|
2002-04-08 |
2005-02-15 |
Agouron Pharmaceuticals, Inc. |
Tropane derivatives useful in therapy
|
GB0209022D0
(en)
|
2002-04-19 |
2002-05-29 |
Imp College Innovations Ltd |
Compounds
|
KR20060021278A
(ko)
*
|
2002-08-15 |
2006-03-07 |
윤킹 리우 |
고체 나노미터 의약 및 이의 제조방법
|
GB0219961D0
(en)
|
2002-08-28 |
2002-10-02 |
Pfizer Ltd |
Oxytocin inhibitors
|
GB0221169D0
(en)
|
2002-09-12 |
2002-10-23 |
Univ Bath |
Crystal
|
KR20050046776A
(ko)
*
|
2002-09-13 |
2005-05-18 |
사이덱스 인크 |
유도체화된 사이클로덱스트린으로 안정화한 수성 충전조성물을 포함하는 캅셀
|
US7230025B2
(en)
|
2002-09-26 |
2007-06-12 |
Pfizer, Inc. |
Pyrazole derivatives
|
US6933312B2
(en)
|
2002-10-07 |
2005-08-23 |
Agouron Pharmaceuticals, Inc. |
Pyrazole derivatives
|
US7323462B2
(en)
|
2002-12-10 |
2008-01-29 |
Pfizer Inc. |
Morpholine dopamine agonists
|
KR20050085563A
(ko)
|
2002-12-13 |
2005-08-29 |
워너-램버트 캄파니 엘엘씨 |
하부요로증상을 치료하기 위한 알파-2-델타 리간드
|
CA2451267A1
(en)
|
2002-12-13 |
2004-06-13 |
Warner-Lambert Company Llc |
Pharmaceutical uses for alpha2delta ligands
|
DE10260873A1
(de)
*
|
2002-12-23 |
2004-07-15 |
Beiersdorf Ag |
Selbstklebende Polymermatrix mit einem Gehalt an Meeresalgenextrakt und Glycerin
|
US7993654B2
(en)
|
2002-12-23 |
2011-08-09 |
Beiersdorf Ag |
Self-adhesive polymer matrix containing sea algae extract
|
DE10260872B4
(de)
|
2002-12-23 |
2013-09-26 |
Beiersdorf Ag |
Verwendung von gelbildendem Polymer, Wasser, Alkohol und Meeresalgenextrakt zur Einstellung von Elastizität und Haftvermögen selbstklebender kosmetischer Polymermatrices
|
US20060177498A1
(en)
*
|
2003-01-22 |
2006-08-10 |
Ramaswami Bharatrajan |
Solid pharmaceutical composition comprising ramipril
|
JP2006517981A
(ja)
*
|
2003-02-17 |
2006-08-03 |
サン・ファーマシューティカル・インダストリーズ・リミテッド |
低用量コルチコステロイド組成物
|
EP1460064A1
(en)
|
2003-03-14 |
2004-09-22 |
Pfizer Limited |
Indole-2-carboxamide derivatives useful as beta-2 agonists
|
MEP34508A
(en)
*
|
2003-03-28 |
2011-02-10 |
Ares Trading Sa |
Cladribine formulations for improved oral and transmucosal delivery
|
BRPI0408848B8
(pt)
*
|
2003-03-28 |
2021-07-27 |
Ares Trading Sa |
composições farmacêuticas de complexo de ciclodextrina-cladribina complexo, usos do referido complexo, bem como processos para a sua preparação
|
CL2004000826A1
(es)
|
2003-04-25 |
2005-03-04 |
Pfizer |
Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
|
US7268147B2
(en)
|
2003-05-15 |
2007-09-11 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
DE10338544B4
(de)
*
|
2003-08-19 |
2017-08-31 |
Janssen Pharmaceutica N.V. |
Buccale Formulierungen des Galanthamins und deren Anwendungen
|
MXPA06002455A
(es)
*
|
2003-09-02 |
2006-08-31 |
Pfizer Prod Inc |
Formas de dosificacion de liberacion sostenida de ziprasidona.
|
EA009457B1
(ru)
|
2003-09-03 |
2007-12-28 |
Пфайзер Инк. |
Бензимидазолоновые соединения, обладающие агонистической активностью в отношении 5-нтрецепторов
|
JP5460947B2
(ja)
|
2003-09-03 |
2014-04-02 |
グラクソ グループ リミテッド |
新規調製方法、塩、組成物及び使用
|
US7220772B2
(en)
|
2003-09-05 |
2007-05-22 |
Pfizer, Inc. |
Pyrazole derivatives
|
US6960300B2
(en)
*
|
2003-09-08 |
2005-11-01 |
Sami Labs Limited |
Process for preparing water soluble diterpenes and their applications
|
CA2537402C
(en)
|
2003-09-12 |
2009-05-05 |
Pfizer Inc. |
Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
|
EA009941B1
(ru)
|
2003-10-03 |
2008-04-28 |
Пфайзер Инк. |
Имидазопиридинзамещённые тропановые производные, обладающие активностью антагониста ccr5 рецептора, для лечения вируса иммунодефицита человека (вич) и воспаления
|
TW200517114A
(en)
|
2003-10-15 |
2005-06-01 |
Combinatorx Inc |
Methods and reagents for the treatment of immunoinflammatory disorders
|
US8389031B2
(en)
|
2005-05-23 |
2013-03-05 |
Kraft Foods Global Brands Llc |
Coated delivery system for active components as part of an edible composition
|
US8591968B2
(en)
|
2005-05-23 |
2013-11-26 |
Kraft Foods Global Brands Llc |
Edible composition including a delivery system for active components
|
US9271904B2
(en)
|
2003-11-21 |
2016-03-01 |
Intercontinental Great Brands Llc |
Controlled release oral delivery systems
|
US8591972B2
(en)
|
2005-05-23 |
2013-11-26 |
Kraft Foods Global Brands Llc |
Delivery system for coated active components as part of an edible composition
|
US8389032B2
(en)
|
2005-05-23 |
2013-03-05 |
Kraft Foods Global Brands Llc |
Delivery system for active components as part of an edible composition having selected particle size
|
US8591974B2
(en)
|
2003-11-21 |
2013-11-26 |
Kraft Foods Global Brands Llc |
Delivery system for two or more active components as part of an edible composition
|
US20050112236A1
(en)
|
2003-11-21 |
2005-05-26 |
Navroz Boghani |
Delivery system for active components as part of an edible composition having preselected tensile strength
|
US8591973B2
(en)
|
2005-05-23 |
2013-11-26 |
Kraft Foods Global Brands Llc |
Delivery system for active components and a material having preselected hydrophobicity as part of an edible composition
|
DE602004031356D1
(de)
|
2003-11-21 |
2011-03-24 |
Zalicus Inc |
Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
|
US8597703B2
(en)
|
2005-05-23 |
2013-12-03 |
Kraft Foods Global Brands Llc |
Delivery system for active components as part of an edible composition including a ratio of encapsulating material and active component
|
US20070020299A1
(en)
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
|
GEP20094781B
(en)
|
2004-01-22 |
2009-09-25 |
Pfizer |
Sulfonamide derivatives for the treatment of diseases
|
GEP20084452B
(en)
|
2004-01-22 |
2008-08-10 |
Pfizer |
Sulfonamide derivatives for the treatment of diseases
|
US7629358B2
(en)
|
2004-03-17 |
2009-12-08 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
WO2005090313A1
(en)
|
2004-03-18 |
2005-09-29 |
Pfizer Limited |
N-(1-arylpyrazol-4l)sulfonamides and their use as parasiticides
|
WO2005092840A1
(en)
|
2004-03-23 |
2005-10-06 |
Pfizer Limited |
Formamide derivatives useful as adrenoceptor
|
US7538141B2
(en)
|
2004-03-23 |
2009-05-26 |
Alan Daniel Brown |
Compounds for the treatment of diseases
|
KR100479367B1
(ko)
*
|
2004-04-13 |
2005-03-29 |
(주) 에프디엘 |
이트라코나졸을 포함하는 경구투여용 항진균제 조성물
|
CN1950348A
(zh)
|
2004-04-30 |
2007-04-18 |
沃尼尔·朗伯有限责任公司 |
治疗中枢神经系统障碍的取代的吗啉化合物
|
EP1742535A4
(en)
*
|
2004-05-06 |
2008-10-15 |
Cydex Pharmaceuticals Inc |
MASTER TASTE PREPARATIONS CONTAINING SERTRALINE AND SULFOALKYLETHER CYCLODEXTRIN
|
US7456164B2
(en)
|
2004-05-07 |
2008-11-25 |
Pfizer, Inc |
3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
|
EP1595881A1
(en)
|
2004-05-12 |
2005-11-16 |
Pfizer Limited |
Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
|
US7737163B2
(en)
|
2004-06-15 |
2010-06-15 |
Pfizer Inc. |
Benzimidazolone carboxylic acid derivatives
|
EA200801608A1
(ru)
|
2004-06-15 |
2008-10-30 |
Пфайзер Инк. |
Производные бензимидазолонкарбоновой кислоты
|
US20050282895A1
(en)
*
|
2004-06-21 |
2005-12-22 |
Dosch Michael H |
Antimicrobial compositions and methods of use thereof
|
US8101208B2
(en)
*
|
2004-08-11 |
2012-01-24 |
Kraft Foods Global Brands Llc |
Sensate compositions and delivery systems therefor
|
NZ552868A
(en)
|
2004-08-12 |
2009-07-31 |
Pfizer |
Triazolopyridinylsulfanyl derivatives as P38 MAP kinase inhibitors
|
US7727565B2
(en)
|
2004-08-25 |
2010-06-01 |
Cadbury Adams Usa Llc |
Liquid-filled chewing gum composition
|
US7955630B2
(en)
|
2004-09-30 |
2011-06-07 |
Kraft Foods Global Brands Llc |
Thermally stable, high tensile strength encapsulated actives
|
US20060068058A1
(en)
*
|
2004-09-30 |
2006-03-30 |
Cadbury Adams Usa Llc |
Thermally stable, high tensile strength encapsulation compositions for actives
|
DK1786785T3
(da)
|
2004-08-26 |
2010-05-31 |
Pfizer |
Enantiomerisk rene aminoheteroaryl-forbindelser som proteinkinasehæmmere
|
CN1325054C
(zh)
*
|
2004-09-29 |
2007-07-11 |
南京师范大学 |
盐酸哌唑嗪的环糊精包合物及其制备方法
|
CA2586179C
(en)
|
2004-11-02 |
2011-02-08 |
Pfizer Inc. |
Sulfonyl benzimidazole derivatives
|
GT200500317A
(es)
*
|
2004-11-05 |
2006-10-27 |
|
Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
|
JP4335120B2
(ja)
|
2004-11-08 |
2009-09-30 |
カゴメ株式会社 |
混合飲料の製造方法
|
US9198448B2
(en)
*
|
2005-02-07 |
2015-12-01 |
Intercontinental Great Brands Llc |
Stable tooth whitening gum with reactive ingredients
|
WO2006091885A2
(en)
|
2005-02-24 |
2006-08-31 |
Dr Pharma Nova, Llc |
A registry method and control system for dea schedule ii-v medicines
|
MX2007011498A
(es)
|
2005-03-17 |
2007-10-11 |
Pfizer |
Derivados de n-(n-sulfonilaminometil)ciclopropanocarboxamida utiles para el tratamiento de dolor.
|
US20080305161A1
(en)
*
|
2005-04-13 |
2008-12-11 |
Pfizer Inc |
Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
|
JP5422203B2
(ja)
|
2005-04-19 |
2014-02-19 |
キングス カレッジ ロンドン |
使用
|
TW200716106A
(en)
*
|
2005-04-24 |
2007-05-01 |
Wyeth Corp |
Methods for modulating bladder function
|
EA200702235A1
(ru)
|
2005-05-04 |
2008-04-28 |
Пфайзер Лимитед |
Производные 2-амидо-6-амино-8-оксопурина в качестве модуляторов toll-подобных рецепторов для лечения рака и вирусных инфекций, таких как гепатит с
|
US7851006B2
(en)
|
2005-05-23 |
2010-12-14 |
Cadbury Adams Usa Llc |
Taste potentiator compositions and beverages containing same
|
AR053296A1
(es)
|
2005-05-23 |
2007-04-25 |
Cadbury Adams Usa Llc |
Composiciones que potencian el sabor y golosinas comestibles y productos de goma de mascar que los contienen
|
US7851005B2
(en)
|
2005-05-23 |
2010-12-14 |
Cadbury Adams Usa Llc |
Taste potentiator compositions and beverages containing same
|
ES2277743B2
(es)
*
|
2005-06-02 |
2008-12-16 |
Universidade De Santiago De Compostela |
Nanoparticulas que comprenden quitosano y ciclodextrina.
|
US20080176865A1
(en)
*
|
2005-06-15 |
2008-07-24 |
Pfizer Limited |
Substituted arylpyrazoles
|
US20080146643A1
(en)
*
|
2005-06-15 |
2008-06-19 |
Pfizer Limited |
Combination
|
US7645786B2
(en)
|
2005-06-15 |
2010-01-12 |
Pfizer Inc. |
Substituted arylpyrazoles
|
EP1893581B1
(en)
|
2005-06-15 |
2010-01-27 |
Pfizer Limited |
Substituted arylpyrazoles for use against parasitites
|
AR054849A1
(es)
|
2005-07-26 |
2007-07-18 |
Wyeth Corp |
Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
|
US20070221236A1
(en)
*
|
2005-10-05 |
2007-09-27 |
Cadbury Adams Usa Llc. |
Cooling compositions including menthyl esters
|
CN100503647C
(zh)
*
|
2005-11-02 |
2009-06-24 |
南京师范大学 |
羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
|
AU2006318349B2
(en)
|
2005-11-28 |
2010-08-19 |
Marinus Pharmaceuticals |
Ganaxolone formulations and methods for the making and use thereof
|
NL2000323C2
(nl)
|
2005-12-20 |
2007-11-20 |
Pfizer Ltd |
Pyrimidine-derivaten.
|
US20070141684A1
(en)
|
2005-12-21 |
2007-06-21 |
Pfizer Inc |
Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
|
AU2006342783B2
(en)
*
|
2005-12-23 |
2010-09-23 |
Intercontinental Great Brands Llc |
Compositions providing a heating sensation for oral or dermal delivery
|
PL2478777T3
(pl)
*
|
2005-12-23 |
2014-10-31 |
Intercontinental Great Brands Llc |
Kompozycja zapewniająca wrażenie chłodzenia zasadniczo podobne do tego zapewnionego przez mentol
|
GB0600406D0
(en)
|
2006-01-10 |
2006-02-15 |
Univ Bath |
Crystal
|
TW200734334A
(en)
*
|
2006-01-13 |
2007-09-16 |
Wyeth Corp |
Treatment of substance abuse
|
GB0600928D0
(en)
|
2006-01-17 |
2006-02-22 |
Novacta Biosystems Ltd |
Improvements relating to lantibiotics
|
BRPI0709164A2
(pt)
*
|
2006-03-24 |
2011-06-28 |
Wyeth Corp |
métodos para modulação da função da bexiga
|
PA8720401A1
(es)
*
|
2006-03-24 |
2008-12-18 |
Wyeth Corp |
Metodos para tratar trastornos cognitivos y otros afines
|
JP2009531435A
(ja)
*
|
2006-03-24 |
2009-09-03 |
ワイス |
うつ病の治療用の新規な治療組み合わせ
|
US20070225334A1
(en)
*
|
2006-03-24 |
2007-09-27 |
Wyeth |
Methods for treating cognitive and other disorders
|
MX2008012092A
(es)
*
|
2006-03-24 |
2008-10-03 |
Wyeth Corp |
Tratamiento del dolor.
|
KR100917809B1
(ko)
|
2006-05-22 |
2009-09-18 |
에스케이케미칼주식회사 |
우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
|
WO2008012538A2
(en)
|
2006-07-25 |
2008-01-31 |
The Secretary Of State For Defence |
Live vaccine strains of francisella
|
AU2007286651A1
(en)
|
2006-08-23 |
2008-02-28 |
Intellect Neurosciences Inc. |
3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom
|
US9744137B2
(en)
|
2006-08-31 |
2017-08-29 |
Supernus Pharmaceuticals, Inc. |
Topiramate compositions and methods of enhancing its bioavailability
|
WO2008031439A2
(en)
|
2006-09-15 |
2008-03-20 |
Stevia Aps |
Treatment of insulin resistance or diseases associated with insulin resistance with bicyclo [ 3.2. i ]octans such as steviol and isosteviol
|
RU2412188C2
(ru)
|
2006-09-21 |
2011-02-20 |
Раквалиа Фарма Инк. |
Производные бензимидазола в качестве селективных ингибиторов кислотной помпы
|
BRPI0719250A2
(pt)
|
2006-10-12 |
2015-06-16 |
Wyeth Corp |
Métodos e composições com opalescência reduzida.
|
RS20090154A
(en)
|
2006-10-18 |
2010-10-31 |
Pfizer Products Inc. |
Biaryl ether urea compounds
|
ATE520651T1
(de)
|
2006-10-23 |
2011-09-15 |
Pfizer |
Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
|
EP2395077A1
(en)
|
2006-11-03 |
2011-12-14 |
Wyeth LLC |
Glycolysis-inhibiting substances in cell culture
|
ES2312308T3
(es)
|
2006-11-17 |
2013-03-26 |
Supernus Pharmaceuticals, Inc. |
Formulaciones de liberación sostenida de topiramato
|
CA2669815A1
(en)
*
|
2006-11-28 |
2008-06-05 |
Marinus Pharmaceuticals |
Nanoparticulate formulations and methods for the making and use thereof
|
ES2645719T3
(es)
*
|
2006-12-04 |
2017-12-07 |
Supernus Pharmaceuticals, Inc. |
Formulaciones de topiramato de liberación inmediata mejoradas
|
WO2008096218A1
(en)
|
2007-02-06 |
2008-08-14 |
Pfizer Inc. |
2-amin0-5, 7-dihydr0-6h- pyrrolo [3, 4-d] pyrimidine derivatives as hsp-90 inhibitors for treating cancer
|
KR20090127326A
(ko)
|
2007-03-02 |
2009-12-10 |
와이어쓰 |
폴리펩티드의 생산을 위한 세포 배양물 중에서 구리 및 글루타메이트의 용도
|
US20100216823A1
(en)
*
|
2007-05-24 |
2010-08-26 |
Pfizer Inc. |
Spirocyclic Derivatives
|
ES2618315T3
(es)
|
2007-05-25 |
2017-06-21 |
Ipsen Pharma S.A.S. |
Ligandos del receptor de melanocortina modificados con hidantoína
|
ES2493641T3
(es)
*
|
2007-06-28 |
2014-09-12 |
Cydex Pharmaceuticals, Inc. |
Administración nasal de soluciones acuosas de corticosteroides
|
GB0714029D0
(en)
|
2007-07-18 |
2007-08-29 |
Novacta Biosystems Ltd |
Lantibiotic-based compounds having antimicrobial activity
|
GB0714030D0
(en)
|
2007-07-18 |
2007-08-29 |
Novacta Biosystems Ltd |
The use of type-B lantibiotic-based compounds having antimicrobial activity
|
AU2008294473B2
(en)
|
2007-09-05 |
2013-12-05 |
Rigel Pharmaceuticals, Inc. |
Xinafoate salt of N4-(2,2-difluoro-4H-benzo[1,4]oxazin-3-one) -6-yl]-5-fluoro-N2-[3-methylaminocar-bonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine
|
CL2008002777A1
(es)
*
|
2007-09-21 |
2010-01-22 |
Wyeth Corp |
Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
|
EP2222183A4
(en)
*
|
2007-11-20 |
2014-02-19 |
Intercontinental Great Brands Llc |
DOUBLE COATED CONFECTIONERY PRODUCT
|
GB2458473A
(en)
|
2008-03-17 |
2009-09-23 |
Imuthes Ltd |
3'-O-allyl- and 3'-O-carboxymethyl- 2'-aminosaccharide derivatives, & amides thereof with peptides, as adjuvants
|
US20090275622A1
(en)
*
|
2008-04-30 |
2009-11-05 |
Prasoona Linga |
Nizatidine formulations
|
JP5600104B2
(ja)
|
2008-08-01 |
2014-10-01 |
ベンティアールエックス ファーマシューティカルズ, インコーポレイテッド |
Toll様受容体アゴニスト処方物およびその使用
|
ES2378513T3
(es)
|
2008-08-06 |
2012-04-13 |
Pfizer Inc. |
Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
|
EP2163253B1
(en)
|
2008-09-15 |
2013-07-17 |
ULLRICH, Oliver |
Extracts from the plant Hornstedtia scyphifera and immunosuppressive effects thereof
|
WO2010058858A1
(ja)
|
2008-11-21 |
2010-05-27 |
ラクオリア創薬株式会社 |
5-ht2b受容体拮抗活性を有する新規ピラゾール-3-カルボキサミド誘導体
|
KR101128450B1
(ko)
*
|
2008-12-11 |
2012-03-28 |
(주)바이오제닉스 |
안정화제로서 β-싸이클로덱스트린 유도체를 포함하는 조성물
|
CA2747248A1
(en)
|
2008-12-17 |
2010-07-15 |
Sharookh Kapadia |
Hepatitis c virus combination therapy
|
MX2011007424A
(es)
|
2009-01-12 |
2011-08-12 |
Icagen Inc |
Derivados de sulfonamida.
|
JP5719312B2
(ja)
|
2009-01-14 |
2015-05-13 |
ノヴァクタ バイオシステムズ リミティッド |
デオキシアクタガルジン誘導体
|
GB0900599D0
(en)
|
2009-01-14 |
2009-02-18 |
Novacta Biosystems Ltd |
Treatment
|
EP2393829A1
(en)
|
2009-02-04 |
2011-12-14 |
Novacta Biosystems Limited |
Actagardine derivatives
|
AU2010223268B2
(en)
|
2009-03-12 |
2015-04-23 |
Haase Investments Gmbh |
Bone morphogenetic protein 2 (BMP2 ) variants with reduced BMP antagonist sensitivity
|
EP2233502A1
(en)
|
2009-03-27 |
2010-09-29 |
Deutsches Rheuma-Forschungszentrum Berlin |
Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
|
WO2010116270A1
(en)
|
2009-04-10 |
2010-10-14 |
Pfizer Inc. |
Ep2/4 agonists
|
GB0906234D0
(en)
|
2009-04-14 |
2009-05-20 |
Secr Defence |
Vaccine
|
US20100291201A1
(en)
*
|
2009-05-14 |
2010-11-18 |
Cerovene, Inc. |
Coated pharmaceutical capsule dosage form
|
AU2010252609A1
(en)
|
2009-05-29 |
2011-11-10 |
Pfizer Limited |
Novel glucocorticoid receptor agonists
|
EP2266563A1
(en)
|
2009-06-11 |
2010-12-29 |
Charité-Universitätsmedizin Berlin (Charité) |
Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
|
WO2011004276A1
(en)
|
2009-07-06 |
2011-01-13 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
CN105669553A
(zh)
|
2009-08-18 |
2016-06-15 |
文蒂雷克斯药品公司 |
作为toll样受体调节剂的取代的苯并氮杂*
|
PT2467380T
(pt)
|
2009-08-18 |
2017-03-07 |
Array Biopharma Inc |
Benzoazepinas substituídas como moduladores de recetor de tipo toll 3
|
WO2011077313A1
(en)
|
2009-12-22 |
2011-06-30 |
Pfizer Inc. |
Piperidinecarboxamides as mpges - 1 inhibitors
|
GEP20156243B
(en)
|
2009-12-23 |
2015-02-10 |
Takeda Pharmaceutical |
Fused heteroaromatic pyrrolidinones as syk inhibitors
|
WO2011083387A1
(en)
|
2010-01-07 |
2011-07-14 |
Pfizer Limited |
Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
|
JP5852966B2
(ja)
|
2010-02-02 |
2016-02-03 |
ノヴァクタ バイオシステムズ リミティッド |
ランチビオティックの塩
|
GB201001688D0
(en)
|
2010-02-02 |
2010-03-17 |
Novacta Biosystems Ltd |
Compounds
|
EP2539358A1
(en)
|
2010-02-25 |
2013-01-02 |
Pfizer Limited |
Peptide analogues
|
WO2011138751A2
(en)
|
2010-05-04 |
2011-11-10 |
Pfizer Inc. |
Heterocyclic derivatives as alk inhibitors
|
WO2011154871A1
(en)
|
2010-06-10 |
2011-12-15 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
WO2012004714A2
(en)
|
2010-07-09 |
2012-01-12 |
Pfizer Limited |
Chemical compounds
|
EP2590951B1
(en)
|
2010-07-09 |
2015-01-07 |
Pfizer Limited |
Benzenesulfonamides useful as sodium channel inhibitors
|
WO2012004706A2
(en)
|
2010-07-09 |
2012-01-12 |
Pfizer Limited |
Chemical compounds
|
CA2804716A1
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Chemical compounds
|
US8772343B2
(en)
|
2010-07-12 |
2014-07-08 |
Pfizer Limited |
Chemical compounds
|
EP2593431B1
(en)
|
2010-07-12 |
2014-11-19 |
Pfizer Limited |
N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
|
JP2013536165A
(ja)
|
2010-07-12 |
2013-09-19 |
ファイザー・リミテッド |
痛みの処置のためのnav1.7阻害薬としてのスルホンアミド誘導体
|
WO2012007861A1
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
|
GB201013509D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
GB201013513D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Formulations
|
GB201013508D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
GB201013507D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
AU2011294888B2
(en)
|
2010-08-24 |
2015-06-18 |
Imperial Innovations Limited |
Glycodendrimers of polypropyletherimine
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
US9011912B2
(en)
|
2010-10-07 |
2015-04-21 |
Abon Pharmaceuticals, Llc |
Extended-release oral dosage forms for poorly soluble amine drugs
|
MX343274B
(es)
|
2010-11-15 |
2016-10-31 |
Viiv Healthcare Uk Ltd |
Inhibidores de la replicacion del vih.
|
WO2012095781A1
(en)
|
2011-01-13 |
2012-07-19 |
Pfizer Limited |
Indazole derivatives as sodium channel inhibitors
|
US8791107B2
(en)
|
2011-02-25 |
2014-07-29 |
Takeda Pharmaceutical Company Limited |
N-substituted oxazinopteridines and oxazinopteridinones
|
WO2012120398A1
(en)
|
2011-03-04 |
2012-09-13 |
Pfizer Limited |
Aryl substituted carboxamide derivatives as trpm8 modulators
|
CN102139115B
(zh)
*
|
2011-03-30 |
2012-12-05 |
天津红日药业股份有限公司 |
阿托伐他汀的环糊精包合物及其口服固体制剂的制备方法
|
CA2832291C
(en)
|
2011-04-05 |
2015-12-01 |
Pfizer Limited |
Pyrrolo[2,3-d)pyrimidine tropomyosin-related kinase inhibitors
|
BR112013029319A2
(pt)
|
2011-05-18 |
2017-01-31 |
Raqualia Pharma Inc |
forma polimorfa i de ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2-benzisoxazol-3-il]oxi}metil)piperidina-1-il]metil}-tetrahidro-2h-pirano-4 carboxílico, forma polimorfa ii de ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2-benzisoxazol-3-il]oxi}metil)piperidina-1-il]metil}-tetrahidro-2h-pirano-4 carboxílico, uso e processo, e método para tratar condições de doença mediadas por atividade receptora de 5-ht4
|
TWI544922B
(zh)
|
2011-05-19 |
2016-08-11 |
愛爾康研究有限公司 |
高濃度歐羅派特錠(olopatadine)眼用組成物
|
EP2723739B1
(en)
|
2011-06-22 |
2016-08-24 |
Takeda Pharmaceutical Company Limited |
Substituted 6-aza-isoindolin-1-one derivatives
|
JP5898767B2
(ja)
|
2011-07-13 |
2016-04-06 |
ファイザー・リミテッドPfizer Limited |
エンケファリン類似体
|
US8575336B2
(en)
|
2011-07-27 |
2013-11-05 |
Pfizer Limited |
Indazoles
|
WO2013017136A1
(en)
|
2011-08-02 |
2013-02-07 |
Pensieve Biosciences Cyprus Limited |
Treatment of cognitive impairment
|
US20160206608A1
(en)
|
2011-08-02 |
2016-07-21 |
Pfizer Inc. |
Crizotinib for use in the treatment of cancer
|
WO2013054185A1
(en)
|
2011-10-13 |
2013-04-18 |
Pfizer, Inc. |
Pyrimidine and pyridine derivatives useful in therapy
|
JP5363636B2
(ja)
|
2011-10-21 |
2013-12-11 |
ファイザー・リミテッド |
新規な塩および医学的使用
|
CN103906746B
(zh)
|
2011-10-26 |
2015-12-09 |
辉瑞有限公司 |
用作钠通道调节剂的(4-苯基咪唑-2-基)乙胺衍生物
|
ES2648901T3
(es)
|
2011-10-28 |
2018-01-08 |
Inhibitaxin Limited |
Derivados de piridazina útiles en terapia
|
ES2593533T3
(es)
|
2011-12-15 |
2016-12-09 |
Pfizer Limited |
Derivados de sulfonamida
|
WO2013093688A1
(en)
|
2011-12-19 |
2013-06-27 |
Pfizer Limited |
Sulfonamide derivatives and use thereof as vgsc inhibitors
|
EP2800740A1
(en)
|
2012-01-04 |
2014-11-12 |
Pfizer Limited |
N-aminosulfonyl benzamides
|
GB201201332D0
(en)
|
2012-01-26 |
2012-03-14 |
Imp Innovations Ltd |
Method
|
JP6002785B2
(ja)
|
2012-02-03 |
2016-10-05 |
ファイザー・インク |
ナトリウムチャネルモジュレーターとしてのベンゾイミダゾールおよびイミダゾピリジン誘導体
|
TW201336527A
(zh)
*
|
2012-02-10 |
2013-09-16 |
Alcon Res Ltd |
具增強的穩定性之水性藥學組成物
|
DK2822953T5
(en)
|
2012-03-06 |
2017-09-11 |
Pfizer |
Macrocyclic derivatives for the treatment of proliferative diseases
|
US9365566B2
(en)
|
2012-03-27 |
2016-06-14 |
Takeda Pharmaceutical Company Limited |
Cinnoline derivatives
|
UY34893A
(es)
|
2012-07-10 |
2014-02-28 |
Takeda Pharmaceutical |
Derivados de azaindol
|
CN104470500A
(zh)
*
|
2012-07-12 |
2015-03-25 |
赛诺菲 |
包含1-(6-{[6-(4-氟苯基)[1,2,4]三唑并[4,3-b]哒嗪-3-基]硫基}-1,3-苯并噻唑-2-基)-3-(2-吗啉-4-基乙基)尿素化合物的抗肿瘤组合物
|
CN104507478A
(zh)
*
|
2012-07-17 |
2015-04-08 |
葛兰素史克有限责任公司 |
用于治疗急性冠状动脉综合征的烟酰胺衍生物
|
WO2014039831A1
(en)
|
2012-09-07 |
2014-03-13 |
Takeda Pharmaceutical Company Limited |
SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES
|
EP2897950A1
(en)
|
2012-09-18 |
2015-07-29 |
Ziarco Pharma Ltd |
2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors
|
JP6254169B2
(ja)
|
2012-09-28 |
2017-12-27 |
ファイザー・インク |
ベンズアミドおよびヘテロベンズアミド化合物
|
CA2885259A1
(en)
|
2012-10-04 |
2014-04-10 |
Pfizer Limited |
Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
|
US20150250785A1
(en)
|
2012-10-04 |
2015-09-10 |
Pfizer Limited |
Tropomyosin-Related Kinase Inhibitors
|
CA2885253A1
(en)
|
2012-10-04 |
2014-04-10 |
Pfizer Limited |
Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors
|
MX2015005506A
(es)
|
2012-11-08 |
2015-08-05 |
Pfizer |
Compuestos heteroaromaticos como ligandos d1 de dopamina.
|
US20150291625A1
(en)
|
2012-11-08 |
2015-10-15 |
Pfizer Inc. |
Heteroaromatic Compounds and their Use as Dopamine D1 Ligands
|
US10179779B2
(en)
|
2012-11-21 |
2019-01-15 |
Raqualia Pharma Inc. |
Polymorph forms
|
AU2013353723B2
(en)
|
2012-12-03 |
2018-02-22 |
Pfizer Inc. |
Novel selective androgen receptor modulators
|
UA112028C2
(uk)
|
2012-12-14 |
2016-07-11 |
Пфайзер Лімітед |
Похідні імідазопіридазину як модулятори гамка-рецептора
|
UA111305C2
(uk)
|
2012-12-21 |
2016-04-11 |
Пфайзер Інк. |
Конденсовані лактами арилу та гетероарилу
|
DK3431475T3
(da)
|
2013-02-21 |
2021-05-25 |
Pfizer |
Faste former af en selektiv CDK4/6-hæmmer
|
JO3377B1
(ar)
|
2013-03-11 |
2019-03-13 |
Takeda Pharmaceuticals Co |
مشتقات بيريدينيل وبيريدينيل مندمج
|
EP2784083A1
(en)
|
2013-03-28 |
2014-10-01 |
Charité - Universitätsmedizin Berlin |
Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
|
EP2792360A1
(en)
|
2013-04-18 |
2014-10-22 |
IP Gesellschaft für Management mbH |
(1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
|
TW201512171A
(zh)
|
2013-04-19 |
2015-04-01 |
Pfizer Ltd |
化學化合物
|
TW201443025A
(zh)
|
2013-04-19 |
2014-11-16 |
Pfizer Ltd |
化學化合物
|
WO2014181213A1
(en)
|
2013-05-10 |
2014-11-13 |
Pfizer Inc. |
Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
|
WO2014207601A1
(en)
|
2013-06-27 |
2014-12-31 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
KR20160029125A
(ko)
|
2013-07-08 |
2016-03-14 |
애브비 인코포레이티드 |
아트라센탄을 포함하는 안정화된 약제학적 용량형
|
CA2915445C
(en)
*
|
2013-07-19 |
2024-04-23 |
Boehringer Ingelheim Vetmedica Gmbh |
Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
|
US8962675B1
(en)
|
2013-09-12 |
2015-02-24 |
Abbvie Inc. |
Atrasentan mandelate salts
|
CN104513253A
(zh)
|
2013-10-01 |
2015-04-15 |
南京波尔泰药业科技有限公司 |
用于治疗增殖性疾病的大环化合物
|
WO2015092610A1
(en)
|
2013-12-20 |
2015-06-25 |
Pfizer Limited |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
WO2015106014A1
(en)
|
2014-01-09 |
2015-07-16 |
Takeda Pharmaceutical Company Limited |
Azaindole derivatives
|
TW201620904A
(zh)
|
2014-01-09 |
2016-06-16 |
武田藥品工業有限公司 |
氮雜吲哚衍生物
|
WO2015157509A1
(en)
*
|
2014-04-10 |
2015-10-15 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating opioid receptor associated diseases
|
US20170197939A1
(en)
|
2014-04-15 |
2017-07-13 |
Pfizer Inc. |
Tropomyosin-Related Kinase Inhibitors Containing Both A 1H-Pyrazole And A Pyrimidine Moiety
|
MA39914A
(fr)
|
2014-04-25 |
2017-03-01 |
Pfizer |
Composés hétéroaromatiques et leur utilisation comme ligands de la dopamine d1
|
PE20170008A1
(es)
|
2014-04-25 |
2017-03-17 |
Pfizer |
Compuestos heteroaromaticos y su uso como ligandos de dopamina d1
|
WO2015162518A1
(en)
|
2014-04-25 |
2015-10-29 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
WO2015166366A1
(en)
|
2014-04-28 |
2015-11-05 |
Pfizer Inc. |
Heterocyclic compounds and their use as dopamine d1 ligands
|
US9856263B2
(en)
|
2014-04-28 |
2018-01-02 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine D1 ligands
|
WO2015170218A1
(en)
|
2014-05-07 |
2015-11-12 |
Pfizer Inc. |
Tropomyosin-related kinase inhibitors
|
PE20161475A1
(es)
|
2014-05-14 |
2017-01-08 |
Pfizer |
Pirazolopiridinas y pirazolopirimidinas
|
RU2698194C2
(ru)
|
2014-05-15 |
2019-08-23 |
Пфайзер Инк. |
Кристаллическая форма 6-[(4r)-4-метил-1,1-диоксидо-1,2,6-тиадиазинан-2-ил]изохинолин-1-карбонитрила
|
KR102471082B1
(ko)
|
2014-05-20 |
2022-11-25 |
라퀄리아 파마 인코포레이티드 |
벤즈이소옥사졸 유도체염
|
EP3148992A1
(en)
|
2014-05-30 |
2017-04-05 |
Pfizer Inc. |
Benzenesulfonamides useful as sodium channel inhibitors
|
CN106572997A
(zh)
|
2014-05-30 |
2017-04-19 |
辉瑞公司 |
作为选择性雄激素受体调节剂的腈衍生物
|
CA2951497C
(en)
|
2014-06-12 |
2019-04-09 |
Pfizer Limited |
Imidazopyridazine derivatives as modulators of the gabaa receptor activity
|
GEP20186933B
(en)
|
2014-06-17 |
2018-12-10 |
Pfizer |
Substituted dihydroisoquinoline compounds
|
WO2015193768A1
(en)
|
2014-06-17 |
2015-12-23 |
Pfizer Inc. |
Aryl fused lactams as ezh2 modulators
|
WO2016009296A1
(en)
|
2014-07-16 |
2016-01-21 |
Pfizer Inc. |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
WO2016009303A1
(en)
|
2014-07-17 |
2016-01-21 |
Pfizer Inc. |
Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
|
WO2016009297A1
(en)
|
2014-07-18 |
2016-01-21 |
Pfizer Inc. |
Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
|
WO2016020784A1
(en)
|
2014-08-05 |
2016-02-11 |
Pfizer Inc. |
N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
|
WO2016034971A1
(en)
|
2014-09-04 |
2016-03-10 |
Pfizer Limited |
Sulfonamides derivatives as urat1 inhibitors
|
US10017529B2
(en)
|
2014-09-16 |
2018-07-10 |
BioPharma Works LLC |
Metformin derivatives
|
GB201417163D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
|
GB201417165D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Treatments for Autoimmune Disease
|
WO2016067143A1
(en)
|
2014-10-28 |
2016-05-06 |
Pfizer Inc. |
N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
|
JP6621477B2
(ja)
|
2014-12-18 |
2019-12-18 |
ファイザー・インク |
ピリミジンおよびトリアジン誘導体ならびにaxl阻害薬としてのそれらの使用
|
TW201636342A
(zh)
|
2014-12-19 |
2016-10-16 |
武田藥品工業有限公司 |
煙黴醇衍生物
|
EP3247371B1
(en)
|
2015-01-22 |
2020-04-01 |
Phytoplant Research S.L. |
Methods of purifying cannabinoids, compositions and kits thereof
|
ES2764840T3
(es)
|
2015-01-28 |
2020-06-04 |
Univ Bordeaux |
Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
|
KR20170119705A
(ko)
|
2015-02-24 |
2017-10-27 |
화이자 인코포레이티드 |
항암제로서 유용한 치환된 뉴클레오시드 유도체
|
WO2016148674A1
(en)
|
2015-03-13 |
2016-09-22 |
Endocyte, Inc. |
Conjugates for treating diseases
|
ES2823049T3
(es)
|
2015-07-31 |
2021-05-05 |
Pfizer |
Derivados de carbamato de 1,1,1-trifluoro-3-hidroxipropan-2-ilo y derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ilo como inhibidores de MAGL
|
US20180193335A1
(en)
*
|
2015-10-12 |
2018-07-12 |
Vikash J. BHAGWANDIN |
Compositions, formulations, packaged pharmaceuticals, and methods of using hedgehog pathway modulators for the sensitization of resistant tumors
|
CA3007595C
(en)
|
2015-12-10 |
2020-08-25 |
Pfizer Limited |
4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain
|
SG11201805331QA
(en)
|
2015-12-24 |
2018-07-30 |
Takeda Pharmaceuticals Co |
Cocrystal, production method thereof, and medicament containing cocrystal
|
KR20180105161A
(ko)
|
2016-01-07 |
2018-09-27 |
씨에스 파마테크 리미티드 |
Egfr 티로신 키나제의 임상적으로 중요한 돌연변이체의 선택적 억제제
|
WO2017119732A1
(en)
|
2016-01-08 |
2017-07-13 |
Samsung Electronics Co., Ltd. |
Electronic device and operating method thereof
|
BR112018013955B1
(pt)
|
2016-01-15 |
2024-01-16 |
Pfizer Inc |
Compostos ligantes de dopamina d3 de 6,7,8,9-tetra-hidro-5h-pirido [2,3- d] azepina, composição farmacêutica que os compreende e uso dos mesmos
|
US11753626B2
(en)
|
2016-03-09 |
2023-09-12 |
Beijing Percans Oncology Co., Ltd. |
Tumor cell suspension cultures and related methods
|
CA2969295A1
(en)
|
2016-06-06 |
2017-12-06 |
Pfizer Inc. |
Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
|
CA3031895A1
(en)
|
2016-07-29 |
2018-02-01 |
Pfizer Inc. |
Cyclic peptides as c5 a receptor antagonists
|
EP3481387A4
(en)
|
2016-08-11 |
2020-04-08 |
Ovid Therapeutics Inc |
METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
|
AU2017311645B2
(en)
|
2016-08-15 |
2021-05-27 |
Pfizer Inc. |
Pyridopyrimdinone CDK2/4/6 inhibitors
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
US10316021B2
(en)
|
2016-11-28 |
2019-06-11 |
Pfizer Inc. |
Heteroarylphenoxy benzamide kappa opioid ligands
|
CA3047730A1
(en)
|
2016-12-20 |
2018-06-28 |
Oligomerix, Inc. |
Quinazolinones that inhibit the formation of tau oligomers and their method of use
|
SG11201906417RA
(en)
|
2017-01-20 |
2019-08-27 |
Pfizer |
1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
|
SG11201906427QA
(en)
|
2017-01-23 |
2019-08-27 |
Pfizer |
Heterocyclic spiro compounds as magl inhibitors
|
WO2018183145A1
(en)
|
2017-03-26 |
2018-10-04 |
Takeda Pharmaceutical Company Limited |
Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of gpr6
|
JOP20180057A1
(ar)
|
2017-06-15 |
2019-01-30 |
Takeda Pharmaceuticals Co |
مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
|
PE20200696A1
(es)
|
2017-06-22 |
2020-06-16 |
Curadev Pharma Ltd |
Moduladores de moleculas pequenas de sting humana
|
TWI779059B
(zh)
*
|
2017-06-30 |
2022-10-01 |
財團法人工業技術研究院 |
化合物用於製備治療自體免疫神經疾病及/或神經退化性疾病之藥物的用途
|
WO2019043634A2
(en)
|
2017-08-30 |
2019-03-07 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS
|
CN118684652A
(zh)
|
2017-09-11 |
2024-09-24 |
克鲁松制药公司 |
SHP2的八氢环戊二烯并[c]吡咯别构抑制剂
|
TW201920108A
(zh)
|
2017-09-25 |
2019-06-01 |
日商武田藥品工業有限公司 |
N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
|
WO2019145552A1
(en)
|
2018-01-29 |
2019-08-01 |
Phytoplant Research S.L |
Methods of purifying cannabinoids using liquid:liquid chromatography
|
TW201942115A
(zh)
|
2018-02-01 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
|
TW201942116A
(zh)
|
2018-02-09 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌劑之四氫喹唑啉衍生物
|
TWI834637B
(zh)
|
2018-03-01 |
2024-03-11 |
日商武田藥品工業有限公司 |
六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
|
TWI741268B
(zh)
|
2018-03-15 |
2021-10-01 |
美商輝瑞股份有限公司 |
干擾素基因刺激劑(sting)的環戊烷為主體之調節劑
|
WO2019180072A1
(en)
|
2018-03-22 |
2019-09-26 |
Bayer Pharma Aktiengesellschaft |
Parenteral pharmaceutical composition comprising neladenoson bialanate
|
WO2019207463A1
(en)
|
2018-04-26 |
2019-10-31 |
Pfizer Inc. |
2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
|
WO2019243823A1
(en)
|
2018-06-21 |
2019-12-26 |
Curadev Pharma Limited |
Azaheterocyclic small molecule modulators of human sting
|
BR112021000109A2
(pt)
|
2018-07-19 |
2021-03-30 |
Pfizer Inc. |
Compostos espiro heterocíclicos como inibidores de magl
|
WO2020076728A1
(en)
|
2018-10-08 |
2020-04-16 |
Takeda Pharmaceutical Company Limited |
SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
|
US11142525B2
(en)
|
2018-11-15 |
2021-10-12 |
Pfizer Inc. |
Azalactam compounds as HPK1 inhibitors
|
US11014908B2
(en)
|
2018-11-29 |
2021-05-25 |
Pfizer Inc. |
Chemical compounds
|
US11266662B2
(en)
|
2018-12-07 |
2022-03-08 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of postpartum depression
|
EP3914597A1
(en)
|
2019-01-23 |
2021-12-01 |
Pfizer Inc. |
Polymorph form of a monophosphate hydrate salt of a known tetrahydroisoquinoline derivative
|
MA54859A
(fr)
|
2019-01-31 |
2022-05-04 |
Pfizer |
Composés 3-carbonylamino-5-cyclopentyl-1h-pyrazole ayant une activité inhibitrice de cdk2
|
WO2020198053A1
(en)
|
2019-03-22 |
2020-10-01 |
Takeda Pharmaceutical Company Limited |
2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-6-yl)-4-methylbenzamide derivatives and similar compounds as ripk2 inhibitors for treating e.g. autoimmune diseases
|
MA55804A
(fr)
|
2019-04-29 |
2022-04-06 |
Solent Therapeutics Llc |
Dérivés de 1,1-dioxyde de 3-amino-4h-benzo[e][1,2,4]thiadiazine en tant qu'inhibiteurs de mrgx2
|
US11339159B2
(en)
|
2019-07-17 |
2022-05-24 |
Pfizer Inc. |
Toll-like receptor agonists
|
KR20220044753A
(ko)
|
2019-07-25 |
2022-04-11 |
큐라데브 파마 프라이버트 리미티드 |
아세틸 조효소 a 신테타제 단쇄 2(acss2)의 소분자 억제제
|
CN114728012A
(zh)
|
2019-08-05 |
2022-07-08 |
马瑞纳斯制药公司 |
用于治疗癫痫持续状态的加奈索酮
|
JOP20220063A1
(ar)
|
2019-09-16 |
2023-01-30 |
Takeda Pharmaceuticals Co |
مشتقات بيريدازين-3(2h)-أون ملتحمة بأزول
|
AU2020355343B2
(en)
|
2019-09-25 |
2023-11-30 |
Pfizer Inc. |
Polyheterocyclic modulators of STING (stimulator of interferon genes)
|
CN110538094B
(zh)
*
|
2019-09-27 |
2022-01-18 |
华南理工大学 |
一种均相亲水和多维稳定的紫檀芪@环糊精包合物及其制备方法
|
MX2022006014A
(es)
|
2019-12-06 |
2022-06-22 |
Marinus Pharmaceuticals Inc |
Ganaxolona para uso en el tratamiento del complejo de esclerosis tuberosa.
|
CN110898015A
(zh)
*
|
2019-12-31 |
2020-03-24 |
上海汉维生物医药科技有限公司 |
一种伊曲康唑制剂的制备方法
|
AU2021219370A1
(en)
|
2020-02-12 |
2022-08-25 |
Curadev Pharma Pvt. Ltd. |
Small molecule STING antagonists
|
US20230137547A1
(en)
|
2020-03-10 |
2023-05-04 |
Seranovo Holding B.V. |
Solid Deep Eutectic Solvent Formulation Platform
|
NL2025092B1
(en)
*
|
2020-03-10 |
2021-10-19 |
Seranovo Holding B V |
Solid deep eutectic solvent formulation platform
|
AR121683A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
|
AR121682A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
|
JP2021167301A
(ja)
|
2020-04-08 |
2021-10-21 |
ファイザー・インク |
Cdk2阻害剤に対する腫瘍適応を抑制するためのcdk4/6およびcdk2阻害剤による同時処置
|
WO2021222888A1
(en)
*
|
2020-05-01 |
2021-11-04 |
University Of Southern California |
Cyclodextrin based anti-microbial therapy
|
KR20230003128A
(ko)
|
2020-05-01 |
2023-01-05 |
화이자 인코포레이티드 |
Hpk1 억제제로서의 아잘락탐 화합물
|
CN115515933A
(zh)
|
2020-05-04 |
2022-12-23 |
武田药品工业株式会社 |
经管腔作用的n-(哌啶-4-基)苯甲酰胺衍生物
|
WO2021224818A1
(en)
|
2020-05-08 |
2021-11-11 |
Pfizer Inc. |
Isoindolone compounds as hpk1 inhibitors
|
TW202214641A
(zh)
|
2020-06-30 |
2022-04-16 |
美商艾瑞生藥股份有限公司 |
Her2突變抑制劑
|
US20240116937A1
(en)
|
2020-07-15 |
2024-04-11 |
Pfizer Inc. |
Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
|
WO2022013692A1
(en)
|
2020-07-15 |
2022-01-20 |
Pfizer Inc. |
Polymorphs of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol mono-hydrochloride
|
WO2022018667A1
(en)
|
2020-07-24 |
2022-01-27 |
Pfizer Inc. |
Combination therapies using cdk2 and cdc25a inhibitors
|
GB202011811D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
GB202011812D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
TW202229239A
(zh)
|
2020-09-23 |
2022-08-01 |
日商武田藥品工業股份有限公司 |
作為ripk2抑制劑之3-(6-胺基吡啶-3-基)苯甲醯胺衍生物
|
US20220168272A1
(en)
*
|
2021-02-22 |
2022-06-02 |
Gholamhossein Yousefi |
Preparation of soluble form of carvedilol
|
US11964978B2
(en)
|
2021-03-18 |
2024-04-23 |
Pfizer Inc. |
Modulators of STING (stimulator of interferon genes)
|
CN113081989B
(zh)
*
|
2021-03-29 |
2022-10-21 |
海南普利制药股份有限公司 |
别嘌醇缓释片剂
|
JP2024512979A
(ja)
|
2021-03-31 |
2024-03-21 |
セブンレス セラピューティクス リミテッド |
疼痛の新しい処置
|
GB202104609D0
(en)
|
2021-03-31 |
2021-05-12 |
Sevenless Therapeutics Ltd |
New Treatments for Pain
|
WO2022214869A2
(en)
|
2021-04-07 |
2022-10-13 |
Lifearc |
Ulk1/2 inhibitors and their use thereof
|
EP4359082A1
(en)
|
2021-06-26 |
2024-05-01 |
Array BioPharma Inc. |
Her2 mutation inhibitors
|
US20240360119A1
(en)
|
2021-08-11 |
2024-10-31 |
Curadev Pharma Pvt. Ltd. |
Small molecule urea derivatives as sting antagonists
|
AU2022325543A1
(en)
|
2021-08-11 |
2024-02-15 |
Curadev Pharma Pvt. Ltd. |
Small molecule sting antagonists
|
IL313022A
(en)
|
2021-12-01 |
2024-07-01 |
Fundaci?N Del Sector P?Blico Estatal Centro Nac De Investigaciones Oncol?Gicas Carlos Iii F S P Cnio |
Compounds
|
WO2023187677A1
(en)
|
2022-03-30 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
|
AR129012A1
(es)
|
2022-04-07 |
2024-07-03 |
Takeda Pharmaceuticals Co |
Derivados de piridazina fusionados
|
WO2024023727A1
(en)
|
2022-07-29 |
2024-02-01 |
Pfizer Inc. |
Novel acc inhibitors
|
WO2024033845A1
(en)
|
2022-08-10 |
2024-02-15 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
CN115487080A
(zh)
*
|
2022-09-23 |
2022-12-20 |
山东博科医用材料有限公司 |
补骨脂酚微胶囊及其制备方法
|
WO2024074827A1
(en)
|
2022-10-05 |
2024-04-11 |
Sevenless Therapeutics Limited |
New treatments for pain
|
TW202428252A
(zh)
|
2022-11-15 |
2024-07-16 |
英商克拉德夫製藥有限公司 |
類Cdc激酶之雜環抑制劑
|
WO2024157205A1
(en)
|
2023-01-26 |
2024-08-02 |
Takeda Pharmaceutical Company Limited |
1-amino-4-phenylphthalazine derivatives useful for the treatment of neurodegenerative diseases
|
WO2024214046A1
(en)
|
2023-04-14 |
2024-10-17 |
Takeda Pharmaceutical Company Limited |
Pyrazolopyrimidine derivatives as inhibitors of nlrp3
|
GB2631397A
(en)
|
2023-06-28 |
2025-01-08 |
Sevenless Therapeutics Ltd |
New treatments for pain
|